Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
· marian chu
AI Briefing
- • Deerfield-backed biotech company licenses exclusive rights to Metis' trispecific TCE for autoimmune disorders.
- • Deal value is approximately $1.62 billion.
- • TCE is for treating autoimmune disorders, a potential new indication.
Context
A US biotechnology company founded by Deerfield Management Company LP has licensed exclusive rights to a preclinical trispecific T-cell engager. The T-cell engager is for autoimmune disorders and is owned by Metis Techbio Co Ltd.
The deal is valued at a potential $1.62 billion.
Advertisement